OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.26 ^USD	+3.28%		+2.44%	-16.56%

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 27, 2024 at 04:08 pm EST

OPKO Health, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 181.9 million compared to USD 185.4 million a year ago. Net loss was USD 65.5 million compared to USD 85.2 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.11 a year ago.
For the full year, revenue was USD 863.5 million compared to USD 1,004.2 million a year ago. Net loss was USD 188.9 million compared to USD 328.4 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.46 a year ago.

Latest news about OPKO Health, Inc.

Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	Mar. 14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	Mar. 13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	Mar. 12	MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	Feb. 28	MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	Feb. 27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing	Feb. 21	MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors	Feb. 20	CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board	Feb. 09	CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform	Feb. 05	MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing	Jan. 19	MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing	Jan. 18	MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing	Jan. 16	MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing	Jan. 11	MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029	Jan. 09	MT
Opko Health Insider Bought Shares Worth $1,344,600, According to a Recent SEC Filing	Jan. 08	MT
Opko Health Insider Bought Shares Worth $514,093, According to a Recent SEC Filing	Jan. 05	MT
OPKO Health Prices $200 Million Convertible Senior Notes Offering	Jan. 05	MT
Top Midday Decliners	Jan. 04	MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday	Jan. 04	MT

Chart OPKO Health, Inc.

Duration

Period

More charts

Company Profile

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Sector

Healthcare Facilities & Services

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OPKO Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.26 USD

Average target price

4.25 USD

Spread / Average Target

+237.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
OPKO HEALTH, INC.	-16.56%	878M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.57B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories